Apimeds Pharmaceuticals US, Inc. (APUS)

ASE – Real Time Price. Currency in USD

0.90

+0.04 (4.90%)

At close: Jun 26, 2026, 4:00 PM EDT

0.91

+0.01 (1.11%)

After-hours: Jun 26, 2026, 7:30 PM EDT

08.06.2026

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Recognition Reflects Dedication, Collaboration, and Purpose-Driven Culture thatEmpower University Employees to Make Last Impacts on Global Students CHARLES TOWN, W.Va., June 8, 2026 /PRNewswire/ -- American Public University System (APUS) has again been certified as a Great Place to Work® , a recognition earned entirely through positive employee feedback.

05.05.2026

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee Parties”), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement.

27.04.2026

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc. (“Apimeds” or “the Company”) (NYSE American: APUS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

16.04.2026

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) resulting from allegations that Apimeds may have issued materially misleading business information to the investing public. So what: If you purchased Apimeds securities you may be entitled to compensation without payment of any out of pocket fees or costs through a continge.

15.04.2026

Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

24.03.2026

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, “Inscobee”), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effec.

11.02.2026

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.

Videos

No Data

There is no data to display

Press releases

08.06.2026

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

05.05.2026

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

27.04.2026

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

16.04.2026

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Apimeds Pharmaceuticals US, Inc. (APUS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apimeds Pharmaceuticals US, Inc. (APUS)

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Videos

No Data

Press releases

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Videos

No Data

Press releases

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Search stocks

Apimeds Pharmaceuticals US, Inc. (APUS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apimeds Pharmaceuticals US, Inc. (APUS)

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Videos

No Data

Press releases

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Videos

No Data

Press releases

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS